Skip to main content

Navigation group

Type at least 3 characters
671 articles

Articles

Study Protocol

Published on 12 Jan 2022

Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study

in Heart Failure and Transplantation

  • Iksung Cho
  • Jaewon Oh
  • In-Cheol Kim
  • Hyemoon Chung
  • Jung-Hee Lee
  • Hyue Mee Kim
  • Young Sup Byun
  • Byung-Su Yoo
  • Eui-Young Choi
  • Wook-Jin Chung
Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2021.765081
  • 1,917 views